A grandmother’s empathy offers a safe space for people with mental health conditions
Supporting the Friendship Bench to improve access to mental healthcare.
Search
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Flying animals to safety with Greater Good Charities
Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.
Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Growing with us
We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Generalized Pustular Psoriasis: Impact Beyond the Skin
Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Dan’s Unique Story
Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.
Fostering Science | Boehringer Ingelheim US
Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.
Look Beyond Stable Video
Learn more about Look Beyond Stable campaign from the perspectives of people living with schizophrenia and others.
Sarcoma: An expert’s perspective
Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, shares his expert perspectives on sarcoma, the importance of early detection, and his hopes for the sarcoma treatment landscape.
Obesity
Obesity
Results from Phase II MASH trial announced at EASL 2024
Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024
New agreement with Quallent expands biosimilar access
Boehringer Ingelheim enters private label agreement for biosimilar
New affordability initiative with GoodRx for our biosimilar
Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
NASH
NASH
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
Discovery Research Global Post-Doc Program
Discovery Research Global Post-Doc Program
Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.